摘要
目的研究乳腺癌组织中血管生成素(Ang-2)和雌激素受体(ER)的表达及生物学意义。方法采用免疫组织化学SABC法,检测85例乳腺癌及42例乳腺纤维腺瘤中Ang-2和ER的表达情况,并评价其与乳腺癌临床病理学因素之间的关系。结果乳腺癌组织中Ang-2阳性率(68.24%,58/85)明显高于乳腺纤维腺瘤(7.14%,3/42)(P<0.01),Ang-2表达与患者年龄、肿瘤大小、病理分型及ER无明显关系(P>0.05)。Ⅲ、Ⅳ期乳腺癌者的Ang-2表达阳性率高于Ⅰ、Ⅱ期乳腺癌者(P<0.05)。有淋巴结转移者的Ang-2阳性率明显高于无淋巴结转移者(P<0.01)。ER在乳腺癌中的阳性率为58.82%(50/85),在乳腺纤维腺瘤中无阳性表达。结论乳腺癌组织中Ang-2有异常表达,与乳腺癌的预后有关。
Objective To investigate the expression and biological significance of Ang-2 and ER in benign and malignant tumor of breast. Methods The expression of Ang-2 in 85 specimens of breast carcinoma and 42 specimens of breast fibroadenona were examined by SABC immunohistochemical method, and the relationship between Ang-2 as well as ER and the clinical pathology was analyzed.Results The positive rate （68.24% ,58/85） of Ang-2 in breast carcinoma was significantly higher than that （7.14% ,3/42） in breast fibroadenona（ P 〈 0.01）, and the expression of Ang-2 was not associated with patients＇ age, tumor size, pathological type and ER status（ P 〉 0.05）. The positive rates of Ang-2 in stage Ⅲ and Ⅳ group were significantly higher than those in stage Ⅰ and Ⅱ group（ P 〈 0.05）. The positive rate of Ang-2 in lymph node metastasis group was significantly higher than that in non lymph node metastasis group （ P 〈 0.01 ）. The positive rate of ER in breast carcinoma was 58.82% （50/85）, ER didn＇t express in breast fibroadenona. Conclusion There is an abnormal expression of Ang-2 in breast carcinoma, and Ang-2 is associated with the prognosis of patients.
出处
《河北医药》
CAS
2009年第2期137-138,共2页
Hebei Medical Journal
基金
河北省科学技术研究与发展指导计划项目(编号:072761263)
